Vertigo Treatment Market

SKU: DMHCIT5209 | Last Updated On: Sep 20 2022 | Available Formats

>Vertigo Treatment Market Expected to reach a high CAGR of 22.1% By 2029:

Vertigo Treatment Market is Segmented By Treatment (Medication (Over-the-counter Drugs, Prescription Drugs), Surgery), By Type (Peripheral Vertigo, Central Vertigo), By End-User (Hospital, Specialty Clinic, Other), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,  2022-2029

Vertigo treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 22.1% during the forecast period (2022-2029). A sudden internal or external spinning sensation is usually brought on by moving the head too fast. Vertigo isn't a medical condition. Rather, it's a symptom of a variety of problems.

North America region is expected to hold the largest market share in the global vertigo treatment market

The increasing research and development for vertigo treatment and the growing prevalence of vertigo are expected to drive market growth.

Vertigo, dizziness, and balance disorders are among the most common health issues among adults. Vertigo affects nearly 40% of American adults at some point in their lives, with women being slightly more susceptible than men. Vertigo and the frequently accompanying nausea and emesis are treated with various medications. Various combinations of acetylcholine, dopamine and histamine receptor antagonism are present in these medications. The American Gastroenterological Association recommends anticholinergics and antihistamines to treat nausea caused by vertigo or motion sickness.

Vertigo Treatment Market Dynamics

The factors influencing the Vertigo Treatment Market are the increasing demand for vertigo treatment and the growing prevalence of vertigo.

The increasing demand for vertigo treatment is expected to drive the market growth in the forecast period

Vertigo and dizziness are among the most common symptoms, with a 17–30% lifetime prevalence. A variety of diseases and conditions can cause them. In a broader sense, vertigo refers to peripheral or central vestibular diseases, which have a lifetime prevalence of up to 10% and an annual incidence of 1.4 percent. Beneficial paroxysmal positional vertigo (BPPV), Meniere's disease (MD), vestibular neuritis, and bilateral vestibulopathy are the most common peripheral vestibular vertigo types migraine of the most common types of central vestibular vertigo. Without treatment, some cases of vertigo improve over time. Some people, such as those with Ménière's disease, have recurring episodes for months or even years. For some types of vertigo, there are specific treatments. BPPV is treated with simple head movements known as the Epley manoeuvre. In the early stages or most cases of vertigo, medicines like prochlorperazine and some antihistamines can help. Many people who suffer from vertigo benefit from vestibular rehabilitation training (VRT), a series of exercises for people who suffer from dizziness and balance issues. Individuals with acute symptoms may seek treatment at any level of the health care system, including emergency services; however, most cases of vertigo are diagnosed and treated at the primary care level. Overuse of imaging procedures, which have a well-defined but limited role in distinguishing vestibular disease from rare but life-threatening conditions like stroke, could be a major driver of direct healthcare costs. Liberatory manoeuvres may provide quick relief in BPPV treatment, the most common type of vertigo in older adults.

Limitations associated with vertigo treatment are expected to hamper the market growth

Antivert (meclizine HCl) is an antihistamine used to prevent or treat motion sickness symptoms such as nausea, vomiting, and dizziness. It can also be used to treat lightheadedness, dizziness, and loss of balance (vertigo) caused by diseases of the inner ear. Antivert may interact with alcohol, cinacalcet, quinidine, terbinafine, or antidepressants, as well as other drugs that make one sleepy or slow their breathing (such as sleeping pills, narcotics, muscle relaxers, or medicines for anxiety, depression, or seizures). Some of the most common antivert side effects are blurred vision, dry mouth, constipation, dizziness, drowsiness, headache, vomiting, or tiredness are all symptoms.

COVID-19 Impact Analysis

Vertigo is a type of dizziness defined as a false sense of movement caused by lesions in the vestibular system, either centrally or peripherally. The link between SARS-COV-2 and ear disorders has yet to be established. Some studies, however, have found a link between SARS-COV-2 infection and newly diagnosed vestibular neuritis. Following the infection, these patients experienced acute vertigo attacks that lasted for varying lengths of time after recovering from COVID-19. Furthermore, a novel and intriguing link have been discovered between COVID-19 and newly diagnosed hearing loss, vertigo, otalgia, and tinnitus. Vertigo has been linked to post-covid infection in some studies. This link is not well understood, and there are few published studies on the subject. In SARS-COV-2, vestibular neuritis is caused by a viral or post-viral inflammatory disorder. Antihistaminics, anti-emetics, benzodiazepines, and anticholinergics are the best treatment options for these patients, and intravenous access is usually used in the early stages because the oral route of administration is ineffective in these patients. Corticosteroids may be used in severe cases. Hence, covid-19 is expected to positively impact the market growth.

Vertigo Treatment Market Segment Analysis

Based on treatment, the medication segment is expected to dominate the market growth

Vertigo caused by migraines usually responds to migraine prevention medications. Nonspecific medications like dimenhydrinate (Dramamine) and meclizine (Bonine) are the best treatments for acute vertigo. Vertigo that occurs within the first five minutes of standing is usually caused by a drop in blood pressure (orthostatic hypotension). (Dramamine) and meclizine (Bonine) are two medications that can be used in this situation. Patients can also use thigh-high compression stockings or abdominal binders, raise the head of the bed, and increase salt and fluid intake. Vertigo medications can help with nausea and vomiting, and some can also help with dizziness. These medications are typically only given for a short time (up to 14 days). In many cases, the doctor will be able to determine what is causing vertigo and will then advise on how to treat it.

Anticholinergics, antihistamines, benzodiazepines, calcium channel antagonists, and dopamine receptor antagonists are among the medications used to treat vertigo. These drugs frequently have multiple effects. They may affect the underlying disease process or modify the severity of symptoms (e.g., vestibular suppressants) (e.g., calcium channel antagonists in the case of vestibular migraine). Most of these drugs, especially those that are sedative, have the potential to change the rate at which the body compensates for vestibular damage.

Vertigo Treatment Market Scope

Metrics

Details

Market CAGR

22.1%

Segments Covered

By Technology, By Technique,  By Application, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Regions Analyzed

North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world.

Major Companies Covered

FzioMed, Inc., Amniox Medical, Inc., Human Regenerative Technologies, LLC, Amnio Technology, LLC, Derma Sciences, MiMedx Group, Inc, and among other major companies listed in the full report

Vertigo Treatment Market Competitive Landscape

With mergers, acquisitions, and product launches, the global vertigo treatment market is moderately competitive. Some of the key players in the market are Auris Medical, Casper Pharma, Mylan N.V., Prestige Consumer Healthcare Inc., Epic Pharma, LLC, WellSpring Pharmaceutical Corporation, ANI Pharmaceuticals, Inc., GlaxoSmithKline, Vintage Labs, Sagent Pharmaceuticals, Inc

Auris Medical

Overview: Altamira Therapeutics is committed to developing therapeutics that address critical unmet medical needs. RNA therapeutics, allergy, viral infections, and inner ear disorders are all areas where the company is currently active. The company was founded in 2003 and is headquartered in Zug, Switzerland.

Product Portfolio: Under the project code AM-125, intranasal betahistine is being developed to treat acute peripheral vertigo.AM-125 is sprayed into the nose. This avoids the effects of first-pass metabolism when betahistine is taken orally.

Frequently Asked Questions

What is the Projected CAGR value of the Vertigo Treatment Market?

Vertigo Treatment Market is expected to grow at a CAGR of 22.1% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Vertigo Treatment Market during 2022-2029

Which is the fastest growing region in the Vertigo Treatment Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest